We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
United Guardian Inc | NASDAQ:UG | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.12 | -1.24% | 9.57 | 9.57 | 10.35 | 9.845 | 9.668 | 9.76 | 10,477 | 22:47:28 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________
FORM
_________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
_______________________________
(Exact name of registrant as specified in its charter)
_______________________________
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
(Address of Principal Executive Offices) (Zip Code)
(
(Registrant's telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
_______________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
On August 9, 2024, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
99.1 | Press Release dated August 9, 2024 | |
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
United-Guardian, Inc. | ||
Date: August 9, 2024 | By: | /s/ Donna Vigilante |
Donna Vigilante | ||
President | ||
EXHIBIT 99.1
United-Guardian Reports Increased Second Quarter Sales & Earnings
HAUPPAUGE, N.Y., Aug. 09, 2024 (GLOBE NEWSWIRE) -- United-Guardian, Inc. (NASDAQ:UG) announced today the financial results for the second quarter and first half of 2024. Sales for the six-month period ended June 30th increased from $5,220,623 in 2023 to $6,645,149 in 2024 and net income increased from $1,217,175 ($0.26 per share) to $1,881,667 ($0.41 per share) for the same period. Second quarter sales increased from $2,650,299 in 2023 to $3,390,205 in 2024, with net income increasing from $461,094 ($0.10 per share) to $956,225 ($0.21 per share).
Donna Vigilante, President of United-Guardian, stated, “We are pleased to announce that sales increased for both the second quarter and the first six months of 2024 compared with the same periods in 2023. Cosmetic ingredient sales increased by 84% in the second quarter and 115% for the first six months of 2024. This increase was primarily attributable to purchases from our largest cosmetic distributor. Sales of medical lubricants increased as well for both the second quarter and first six months of 2024 by 15% and 9% respectively. Pharmaceutical product sales increased in the second quarter by 3% but decreased 13% for the first six months of 2024. The decrease for the six-month period was attributable to a shutdown we experienced with our contract manufacturer for Renacidin® late last year. Renacidin production resumed in late March, and sales are in the process of recovering.”
United-Guardian is a manufacturer of cosmetic ingredients, pharmaceuticals, medical lubricants, and sexual wellness ingredients.
Contact: | Donna Vigilante |
(631) 273-0900 | |
dvigilante@u-g.com |
NOTE: This press release contains both historical and "forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements about the company’s expectations or beliefs concerning future events, such as financial performance, business prospects, and similar matters, are being made in reliance upon the “safe harbor” provisions of that Act. Such statements are subject to a variety of factors that could cause our actual results or performance to differ materially from the anticipated results or performance expressed or implied by such forward-looking statements. For further information about the risks and uncertainties that may affect the company’s business please refer to the company's reports and filings with the Securities and Exchange Commission.
Financial Results for the Three and Six Months Ended June 30, 2024 and 2023 STATEMENTS OF INCOME (unaudited) | ||||||||||||||||
THREE MONTHS ENDED JUNE 30, | SIX MONTHS ENDED JUNE 30, | |||||||||||||||
2024 | 2023 | 2024 | 2023 | |||||||||||||
Net sales | $ | 3,390,205 | $ | 2,650,299 | $ | 6,645,149 | $ | 5,220,623 | ||||||||
Costs and expenses: | ||||||||||||||||
Cost of sales | 1,561,090 | 1,429,407 | 3,117,580 | 2,523,002 | ||||||||||||
Operating expenses | 602,777 | 574,093 | 1,171,642 | 1,092,039 | ||||||||||||
Research and development expense | 111,660 | 128,729 | 214,642 | 255,688 | ||||||||||||
Total costs and expenses | 2,275,527 | 2,132,229 | 4,503,864 | 3,870,729 | ||||||||||||
Income from operations | 1,114,678 | 518,070 | 2,141,285 | 1,349,894 | ||||||||||||
Other income (expense): | ||||||||||||||||
Investment income | 100,007 | 54,950 | 198,080 | 102,582 | ||||||||||||
Net (loss) gain on marketable securities | (9,501 | ) | 7,479 | 31,995 | 80,180 | |||||||||||
Total other income | 90,506 | 62,429 | 230,075 | 182,762 | ||||||||||||
Income before provision for income taxes | 1,205,184 | 580,499 | 2,371,360 | 1,532,656 | ||||||||||||
Provision for income taxes | 248,959 | 119,405 | 489,693 | 315,481 | ||||||||||||
Net income | $ | 956,225 | $ | 461,094 | $ | 1,881,667 | $ | 1,217,175 | ||||||||
Earnings per common share (basic and diluted) | $ | 0.21 | $ | 0.10 | $ | 0.41 | $ | 0.26 | ||||||||
Weighted average shares (basic and diluted) | 4,594,319 | 4,594,319 | 4,594,319 | 4,594,319 |
Cover |
Aug. 09, 2024 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Aug. 09, 2024 |
Entity File Number | 001-10526 |
Entity Registrant Name | United-Guardian, Inc. |
Entity Central Index Key | 0000101295 |
Entity Tax Identification Number | 11-1719724 |
Entity Incorporation, State or Country Code | DE |
Entity Address, Address Line One | 230 Marcus Boulevard |
Entity Address, City or Town | Hauppauge |
Entity Address, State or Province | NY |
Entity Address, Postal Zip Code | 11788 |
City Area Code | 631 |
Local Phone Number | 273-0900 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, $0.10 par value per share |
Trading Symbol | UG |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
1 Year United Guardian Chart |
1 Month United Guardian Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions